Screening, Assessment, and Treatment of Substance Use Disorders: Evidence based Practices, Community and Organizational Setting in the Era of Integrated Care

2019 ◽  
Vol 16 (6) ◽  
pp. 691-692
Author(s):  
Yolanda Bogan
Author(s):  
Alan A. Wartenberg

The central premise of this chapter on providing integrated care for both pain and addiction is that all patients presenting with pain are at risk for development of substance use disorders. Assessment and treatment of the complex interplay between pain syndromes and substance use disorders proceed most productively by employing an integrated model, with a multidisciplinary approach and with employment of multiple diagnostic instruments. The author describes an integrated care model as it applies to each of the common substances of use: opioids, tobacco, alcohol, benzodiazepines, cannabinoids, barbiturates, and stimulants. The basis for a decision to refer for evaluation or treatment is described. The chapter concludes with an argument for collaboration between disciplines, notably pain medicine and addiction medicine, as being the current standard of acceptable care for patients whose illnesses dwell in both camps. A separate text box provides additional information and resources bearing on this chapter’s topics.


Author(s):  
Kathleen Broad ◽  
Tony P. George

This chapter provides a practical and evidence-based approach to the screening, assessment, and treatment of substance use disorders (SUDs) in the primary care setting. SUDs according to the DSM-5 is defined and the evidence for validated screening tools in the primary care setting is discussed. A primary care approach to the assessment of SUDs is described in detail including assessing readiness to change using the transtheoretical model, motivational interviewing techniques, assessing medical and psychiatric comorbidities, and determining treatment setting using the ASAM Criteria. A detailed overview of the epidemiology, acute and chronic effects, and withdrawal syndromes associated with alcohol, opioid, stimulant, cannabis, and nicotine is provided. Finally, behavioural interventions for SUDs including relapse-prevention and evidence-based pharmacotherapies for tobacco, alcohol, and opioids use disorders are reviewed.


Sign in / Sign up

Export Citation Format

Share Document